Full history for every metric is available with a Kvantra account

Stock profile

CardieX Limited (CDX.AX)

Country: AustraliaSector: HealthcareIndustry: Medical - DevicesExchange: ASX

Delisted · last close 17 Oct 2025

Current price
0.03 AUD-3.57%
Last close 17 Oct 2025
Benchmarks

Key financial summary

Financials in AUD
202020212022202320242025TTM
Total revenueAUD m45451166
Operating profitAUD m-12-12
Net profitAUD m-3-6-12-19-7-13-13
EPS reportedAUD-0.04-0.04
Operating cashflow per shareAUD-0.03-0.03
Capex per shareAUD0.000.00
FCF per shareAUD-0.03-0.03
Free cash flowAUD m-11-11
Net debtAUD m11
Book value equityAUD m66
Book value per shareAUD0.020.01
Number of sharesm354.14412.06
DPS (TTM paid)AUD0.000.00

Financial summary

Financials in AUD
202020212022202320242025TTM
Value
P/E TTMx--
P/B LTMx2.533.54
P/S LTMx2.253.15
P/FCF LTMx-1.30-1.81
EV/EBITDA LTMx-1.31-1.74
EV/Sales LTMx2.453.28
Earnings Yield LTM%-93.36%-103.74%
FCF Yield%-77.11%-55.16%
Quality
ROE%-236.19%-273.06%
ROIC%-126.67%-126.67%
Operating margin%-187.45%-187.45%
Gross margin%78.27%78.27%
FCF/Sales%-173.86%-173.86%
Growth and momentum
EPS Growth YoY%--
Sales Growth YoY%-42.39%-42.39%
Net Income Growth YoY%--
FCF Growth%--
Operating Profit Growth%--
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%0.00%0.00%
Payout Ratio%0.00%0.00%
FCF/Debtx-2.96-2.96
Net Debt/EBITDAx-0.11-0.11
EBIT/Net interestx-17.78-17.78
Net debt/market cap%5.47%3.92%
Net debt/Equityx0.140.14
Gross debt/equityx0.660.66

Company overview

CardieX Limited, established in Sydney, Australia, in 1994, is a global innovator specializing in the design, production, and distribution of medical devices for cardiovascular health management. Operating across the Americas, Europe, and the Asia Pacific, the company collaborates with pharmaceutical firms by providing its advanced SphygmoCor XCEL devices. It also delivers comprehensive laboratory and data management services, ensuring high-quality datasets for clinical trial sponsors. Under its CONNEQT brand, CardieX develops cutting-edge home vascular health solutions, which encompass remote patient monitoring, tools for decentralized clinical trials, specialized wearables, and medical applications. A flagship product is the CONNEQT Pulse device, a home-based system that leverages proprietary SphygmoCor technology to precisely measure central blood pressure, arterial waveforms, and other vital arterial health parameters. CardieX serves a diverse clientele, including hospitals, clinics, research institutions, and pharmaceutical companies. The company also maintains a strategic alliance with LifeQ, Inc., focusing on wearable device technology. CardieX Limited was formerly known as AtCor Medical Holdings Limited until its name change in June 2018.

WebsiteN/A
IndustryMedical - Devices
CountryAustralia
Trades inAUD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Delisted · last close 17 Oct 2025

CardieX Limited (CDX.AX)

CDX.AX · ASX · Healthcare
0.03 AUD-3.57%
Benchmarks
Financialsin AUD
20242025TTM
About

CardieX Limited, established in Sydney, Australia, in 1994, is a global innovator specializing in the design, production, and distribution of medical devices for cardiovascular health management. Operating across the Americas, Europe, and the Asia Pacific, the company collaborates with pharmaceutical firms by providing its advanced SphygmoCor XCEL devices. It also delivers comprehensive laboratory and data management services, ensuring high-quality datasets for clinical trial sponsors. Under its CONNEQT brand, CardieX develops cutting-edge home vascular health solutions, which encompass remote patient monitoring, tools for decentralized clinical trials, specialized wearables, and medical applications. A flagship product is the CONNEQT Pulse device, a home-based system that leverages proprietary SphygmoCor technology to precisely measure central blood pressure, arterial waveforms, and other vital arterial health parameters. CardieX serves a diverse clientele, including hospitals, clinics, research institutions, and pharmaceutical companies. The company also maintains a strategic alliance with LifeQ, Inc., focusing on wearable device technology. CardieX Limited was formerly known as AtCor Medical Holdings Limited until its name change in June 2018.

IndustryMedical - Devices
CountryAustralia
Trades inAUD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free